Ganlu Traditional Medicine

Based in China, Ganlu Traditional Medicine specializes in the production and distribution of traditional Tibetan medicinal products, focusing on high-quality herbal formulations for various health conditions. Ganlu Traditional Medicine is engaged in producing traditional Tibetan medicine. Founded in 1996 and headquartered in Lhasa, China, the company has successfully completed one deal, with the most recent deal date being September 28, 2025. The founder's history and prior ventures are not documented in available resources.

Tibet Ganlu Tibetan Medicine Co. , Ltd. specializes in the production and distribution of traditional Tibetan medicinal products, emphasizing high-quality herbal formulations. Their flagship product, Ganlu Qishiwei Pearl Pills, is designed to alleviate various health conditions.

The company draws from a rich heritage dating back to 1696, blending ancient Tibetan medical wisdom with modern pharmacological principles. Currently, it offers 55 state-approved medicinal products, with 21 included in the National Medical Insurance Directory, ensuring acceptance within China's healthcare framework. Their customer base includes healthcare providers, traditional medicine practitioners, and consumers seeking alternative health solutions, with distribution extending nationwide in China, beyond Tibet. Tibet Ganlu Tibetan Medicine Co.

, Ltd. generates revenue through direct sales of its medicinal products to healthcare institutions and consumers. The business model primarily involves B2B sales to retailers and traditional medicine outlets, complemented by direct-to-consumer sales. Key products, such as Ganlu Qishiwei Pearl Pills, contribute significantly to the revenue streams, with pricing reflective of the quality associated with traditional Tibetan medicine.

The company utilizes patented technologies and unique formulations to differentiate its offerings in the herbal medicine market. Regular sales agreements and promotional partnerships with healthcare providers sustain business transactions, ensuring a steady demand for its diverse product range. Ganlu Traditional Medicine plans to use the strategic investment received in September 2025 from CCT Fund Management, Chengdu Wuhou Industry Investment & Development Group Co. , Ltd.

, Guangzhou Pharmaceutical Capital, and Tibet Trust to support their growth initiatives. The company is designing new products and aims to launch them by 2026, while also targeting expansion into international markets in Asia and Europe by 2027. The recent funding will help facilitate these product developments and market expansions.